IFN-λ Modulates the Migratory Capacity of Canine Mammary Tumor Cells via Regulation of the Expression of Matrix Metalloproteinases and Their Inhibitors

Cells. 2021 Apr 23;10(5):999. doi: 10.3390/cells10050999.

Abstract

Interactions between neoplastic and immune cells taking place in tumors drive cancer regulatory mechanisms both in humans and animals. IFN-λ, a potent antiviral factor, is also secreted in the tumor; however, its role in tumor development is still unclear. In our study, we investigate the influence of IFN-λ on the canine mammary tumor (CMT) cell survival and their metastatic potential in vitro. First, we examined, by Western blot, the expression of the IFN-λ receptor complex in three CMT cell lines (P114, CMT-U27 and CMT-U309). We showed that only two cell lines (P114 and CMT-U27) express both (IL-28RA and IL-10Rb) receptor subunits and respond to IFN-λ treatment by STAT phosphorylation and the expression of interferon-stimulated genes. Using MTT, crystal violet and annexin-V assays, we showed a minimal role of IFN-λ in CMT viability. However, IFN-λ administration had a contradictory effect on cell migration in the scratch test, namely, it increased P114 and decreased CMT-U27 motility. Moreover, we demonstrated that this process is related to the expression of extracellular matrix metalloproteinases and their inhibitors; furthermore, it is independent of Akt and ERK signaling pathways. To conclude, we showed that IFN-λ activity is reliant on the expression of two receptor subunits and tumor type, but further investigations are needed.

Keywords: Akt; ERK; IL-28; IL-29; STAT; apoptosis; breast cancer; interferon-stimulated-genes; metastasis; proliferation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Dogs
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Interferons / pharmacology*
  • Mammary Neoplasms, Animal / drug therapy
  • Mammary Neoplasms, Animal / metabolism
  • Mammary Neoplasms, Animal / pathology*
  • Matrix Metalloproteinase Inhibitors / metabolism*
  • Matrix Metalloproteinases / genetics
  • Matrix Metalloproteinases / metabolism*
  • Receptors, Interferon / genetics
  • Receptors, Interferon / metabolism*
  • Receptors, Interleukin-10 / genetics
  • Receptors, Interleukin-10 / metabolism*

Substances

  • Antineoplastic Agents
  • Matrix Metalloproteinase Inhibitors
  • Receptors, Interferon
  • Receptors, Interleukin-10
  • Interferons
  • Matrix Metalloproteinases